Evidence map›Paper›PMID 30670062›Full record

ArticleJournal of ovarian research2019

Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer.

Ying Ying Su, Li Sun, Zhi Rui Guo, Jin Chang Li, Ting Ting Bai, Xiao Xiao Cai, Wen Han Li, Ye Fei Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ovarian research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ying Ying SuThe Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210011, Jiangsu, China.
Li SunThe Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210011, Jiangsu, China.
Zhi Rui GuoThe Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210011, Jiangsu, China.
Jin Chang LiThe Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, China.
Ting Ting BaiThe Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210011, Jiangsu, China.
Xiao Xiao CaiThe Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210011, Jiangsu, China.
Wen Han LiThe Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210011, Jiangsu, China.
Ye Fei ZhuThe Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210011, Jiangsu, China. zhuyf@njmu.edu.cn.

Funding

he Science and Technology Development Foundation of Nanjing Medical University of China No.2015NJMUZD037Research and Innovation Program for graduate students of Jiangsu Province No.JX22013385Research and Innovation Program for graduate students of Jiangsu Province NO.KYCX17_1292the International Exchange and Cooperation Foundation of Nanjing Medical University No.C063, D009the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (No.17KJB310007)the Science and Technology Support Project of Jiangsu Province No.BE2017763
6 · The paper itself

Abstract

backgroundOvarian cancer (OC) is associated with high mortality in gynecological oncology; this is mainly due to the low diagnosis rate. Exosomal miRNA has demonstrated potential as a tumor biomarker. We aimed to explore the diagnostic potential of serum exosomal miR-1307 and miR-375 for OC.

methodsThe first six candidate miRNAs were selected from the previous literature. The relative quantification of qRT-PCR was used to screen for the stability of exosomal miRNAs, followed by validation of the cohort. ROC analysis was employed to analyze the specificity and sensitivity of exosomal miRNA.

resultsMiR-1307 and miR-375 were confirmed stably existing in serum exosomes of OC. Moreover, miR-1307 and miR-375 were both significantly up-regulated in serum exosomes of OC compared to ovarian benign and healthy groups. The overexpressed miRNAs showed independent diagnostic power and enhanced the diagnostic accuracy of traditional biomarkers when combined with CA-125 and HE4. MiR-1307 was associated with tumor staging, and miR-375 was associated with lymph node metastasis of OC.

conclusionOur results suggest that serum exosomal miR-1307 and miR-375 could serve as potential tumor biomarkers to improve diagnostic efficiency for OC.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorExosomesFemaleHumansLymphatic MetastasisMicroRNAsMiddle AgedNeoplasm StagingOvarian NeoplasmsUp-RegulationYoung AdultBiomarkers, TumorMicroRNAsMIRN1307 microRNA, humanMIRN375 microRNA, humanBiomarkermicroRNAOvarian cancerSerum exosome

Identifiers

PMID30670062
PMCPMC6341583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.